Articles From: Biogen Idec to Present at the Morgan Stanley Global Healthcare Conference 2014 to BioMarin Announces Second Quarter 2014 Financial Results


Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will present at the Morgan Stanley Global Healthcare Conference 2014.
Sign-up for Biogen Idec to Present at the Morgan Stanley Global Healthcare Conference 2014 investment picks
Today Biogen Idec (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved PLEGRIDY TM (peginterferon beta-1a), a new treatment for people with relapsing forms of multiple sclerosis (RMS). PLEGRIDY , the only pegylated beta interferon approved for use in RMS, is dosed once every two weeks and can be administered subcutaneously with the PLEGRIDY PEN, a new, ready-to-use autoinjector, or a prefilled syringe.
Sign-up for Biogen Idec’s PLEGRIDY™(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis investment picks
BIOLASE, Inc. (NASDAQ:BIOL), the world’s leading manufacturer and distributor of dental lasers, today announced that as a key part of its ongoing transformation, it has formed a new Dental Professional Advisory Board.
Sign-up for BIOLASE Announces Formation of Dental Professional Advisory Board investment picks
BIOLASE, Inc. (BIOL), the world’s leading dental laser manufacturer and distributor, announced today that non-executive board member Federico Pignatelli yesterday withdrew his lawsuit against the Company and four other members of BIOLASE’s board of directors.
Sign-up for BIOLASE Announces That Non-Executive Board Member Federico Pignatelli Has Withdrawn His Lawsuit against Company investment picks
BIOLASE, Inc. (NASDAQ:BIOL), the world’s leading manufacturer and distributor of dental lasers, today announced that as part of its ongoing transformation it has created a new Global Commercialization Team and has hired two seasoned executives to lead its worldwide sales and marketing organizations.
Sign-up for BIOLASE Creates Global Commercialization Team investment picks
BIOLASE, Inc. (BIOL), the world’s leading dental laser manufacturer and distributor, announced today that it held its Annual Meeting of Stockholders on Wednesday, August 27, at the Company's corporate headquarters in Irvine, CA, as scheduled.
Sign-up for BIOLASE Holds Annual Meeting of Stockholders investment picks
BIOLASE, Inc. (NASDAQ:BIOL), the world’s leading manufacturer and distributor of dental lasers, today announced that Alexander K.
Sign-up for BIOLASE Names Alexander K. Arrow, M.D. Chief Medical Officer investment picks
BIOLASE, Inc. (NASDAQ:BIOL), the world’s leading manufacturer and distributor of dental lasers, today announced that Jeffrey M.
Sign-up for BIOLASE Names Jeffrey M. Nugent Permanent President and Chief Executive Officer investment picks
BIOLASE, Inc. (NASDAQ:BIOL), the world’s leading manufacturer and distributor of dental lasers, today reported unaudited financial results for the second quarter and six months ended June 30, 2014.
Sign-up for BIOLASE Reports 2014 Second Quarter Results investment picks
BIOLASE, Inc. (NASDAQ:BIOL), the world’s leading dental laser manufacturer and distributor, today sent a letter to its stockholders.
Sign-up for BIOLASE Sends Letter to Stockholders investment picks
BIOLASE, Inc. (NASDAQ:BIOL), the world’s leading dental laser manufacturer and distributor, announced today that the Company will host a conference call on Thursday, August 7th, at 4:30 p.m. Eastern Time to discuss its operating results for the second quarter and six months ended June 30, 2014, and to answer questions.
Sign-up for BIOLASE to Host Second Quarter Financial Results Conference Call on August 7, 2014 investment picks
BIOLASE, Inc. (NASDAQ:BIOL), the world’s leading dental laser manufacturer and distributor, announced today that Jack W.
Sign-up for BIOLASE to Raise $12 Million from Institutional and Individual Investors in Private Placement investment picks
Company to Produce DuraGraft® Tissue Preservation Solution for Storage of Harvested Veins BOTHELL, Wash.
Sign-up for BioLife Solutions Announces Manufacturing Agreement With Somahlution LLC investment picks
Year-to-date Core Product Revenue up 27% Over 2013 BOTHELL, Wash.
Sign-up for BioLife Solutions Announces Preliminary Revenue for Q3 2014 of $1.2 Million investment picks
Conference Call and Webcast at 4:30pm Eastern Time BOTHELL, Wash.
Sign-up for BioLife Solutions Announces Second Quarter 2014 Results investment picks
President-Elect of the Society for Cryobiology and Former Cell Therapy Executive Join Leading Clinicians, Developers, and Consultants in the Biobanking, Drug Discovery, and Regenerative Medicine Markets BOTHELL, Wash.
Sign-up for BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board investment picks
Clinical Grade Cell and Tissue Biopreservation Media Products Enabling Commercialization of Cellular Immunotherapies and Restorative Therapies BOTHELL, Wash.
Sign-up for BioLife Solutions CryoStor® AND HypoThermosol® Now Embedded In 130 Regenerative Medicine Clinical Trials investment picks
Combination of CryoStor and Dry Ice Offers Alternative High Quality, More Cost-Effective Logistics to Home-Brew Freeze Media and Liquid Nitrogen Shippers BOTHELL, Wash.
Sign-up for BioLife Solutions CryoStor® Demonstrates Superior Cell Preservation In Multicenter Biobanking Study investment picks
Super-insulating Shippers Transmit Payload Location and Critical Status Information to Enable Cloud-based Cold Chain Management BOTHELL, Wash.
Sign-up for BioLife Solutions Forms biologistex CCM(SM) Joint Venture with SAVSU® Technologies to Market Intelligent, Controlled Temperature Containers for Biologics investment picks
BioLineRx Ltd.
Sign-up for BioLineRx Announces Results from Phase 1/2 Study for Celiac Treatment investment picks
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the second quarter ended June 30, 2014.
Sign-up for BioLineRx Reports Second Quarter 2014 Financial Results investment picks
2014/9/2
BioLineRx Ltd.
Sign-up for BioLineRx to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York investment picks
2014/7/30
BioLineRx Ltd.
Sign-up for BioLineRx to Report Second Quarter 2014 Results on August 6, 2014 investment picks
- VIMIZIM ® Sales Top $14 million in First Full Quarter of Sales SAN RAFAEL, Calif., July 30, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced financial results for the second quarter ended June 30, 2014.
Sign-up for BioMarin Announces Second Quarter 2014 Financial Results investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Biogen Idec to Present at the Morgan Stanley Global Healthcare Conference 2014 to BioMarin Announces Second Quarter 2014 Financial Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices